WO2001085796A3 - Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage - Google Patents

Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage Download PDF

Info

Publication number
WO2001085796A3
WO2001085796A3 PCT/EP2001/005478 EP0105478W WO0185796A3 WO 2001085796 A3 WO2001085796 A3 WO 2001085796A3 EP 0105478 W EP0105478 W EP 0105478W WO 0185796 A3 WO0185796 A3 WO 0185796A3
Authority
WO
WIPO (PCT)
Prior art keywords
pathological
growth factor
pigf
arteriogenesis
vascular leakage
Prior art date
Application number
PCT/EP2001/005478
Other languages
French (fr)
Other versions
WO2001085796A2 (en
Inventor
Peter Carmeliet
Desire Collen
Falco Sandro De
Ruvo Menotti
Original Assignee
Vlaams Interuniv Inst Biotech
D Collen Res Foundation Vzw
Peter Carmeliet
Desire Collen
Falco Sandro De
Ruvo Menotti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8171493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001085796(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP01943357A priority Critical patent/EP1297016B1/en
Priority to CA2407858A priority patent/CA2407858C/en
Priority to DE60118186T priority patent/DE60118186T2/en
Priority to AU2001265953A priority patent/AU2001265953B2/en
Priority to AU6595301A priority patent/AU6595301A/en
Application filed by Vlaams Interuniv Inst Biotech, D Collen Res Foundation Vzw, Peter Carmeliet, Desire Collen, Falco Sandro De, Ruvo Menotti filed Critical Vlaams Interuniv Inst Biotech
Publication of WO2001085796A2 publication Critical patent/WO2001085796A2/en
Publication of WO2001085796A3 publication Critical patent/WO2001085796A3/en
Priority to US10/291,979 priority patent/US7482004B2/en
Priority to US12/265,046 priority patent/US20090074765A1/en
Priority to US12/341,177 priority patent/US20090162354A1/en
Priority to US12/400,993 priority patent/US20090238826A1/en
Priority to US13/470,615 priority patent/US20120263710A1/en
Priority to US13/785,643 priority patent/US20130183310A1/en
Priority to US13/785,253 priority patent/US20130177564A1/en
Priority to US13/785,559 priority patent/US20130177565A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to the field of pathological angiogenesis and arteriogenesis. In particular, the invention describes a stress induced phenotype in a transgenic mouse (PIGF-/-) which does not produce Placental Growth Factor (PIGF) and which demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. It is revealed that PIGF-deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumour formation, pulmonary hypertension, vascular leakage (oedema formation) and inflammatory disorders. The invention thus relates to molecules which can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monoclonal antibodies and tetrameric peptides. The invention further relates to the use of these molecules to treat the latter pathological processes.
PCT/EP2001/005478 2000-05-12 2001-05-10 Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage WO2001085796A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
EP01943357A EP1297016B1 (en) 2000-05-12 2001-05-10 Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
CA2407858A CA2407858C (en) 2000-05-12 2001-05-10 Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
DE60118186T DE60118186T2 (en) 2000-05-12 2001-05-10 USE OF PLAZENTA GROWTH FACTOR INHIBITORS FOR THE TREATMENT OF A PATHOLOGICAL ANGIOGENESIS, PATHOLOGICAL ARTERIOGENESIS, INFLAMMATION, TUMOR FORMATION AND / OR VASCULARITY OF LIQUIDITY (ÖDEM)
AU2001265953A AU2001265953B2 (en) 2000-05-12 2001-05-10 Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
AU6595301A AU6595301A (en) 2000-05-12 2001-05-10 Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
US10/291,979 US7482004B2 (en) 2000-05-12 2002-11-11 Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage
US12/265,046 US20090074765A1 (en) 2000-05-12 2008-11-05 Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage
US12/341,177 US20090162354A1 (en) 2000-05-12 2008-12-22 Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage
US12/400,993 US20090238826A1 (en) 2000-05-12 2009-03-10 Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage
US13/470,615 US20120263710A1 (en) 2000-05-12 2012-05-14 Administering anti-placental growth factor antibodies
US13/785,559 US20130177565A1 (en) 2000-05-12 2013-03-05 Administering anti-placental growth factor antibodies
US13/785,643 US20130183310A1 (en) 2000-05-12 2013-03-05 Administering anti-placental growth factor antibodies
US13/785,253 US20130177564A1 (en) 2000-05-12 2013-03-05 Administering anti-placental growth factor antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00201714 2000-05-12
EP00201714.3 2000-05-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/291,979 Continuation US7482004B2 (en) 2000-05-12 2002-11-11 Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage

Publications (2)

Publication Number Publication Date
WO2001085796A2 WO2001085796A2 (en) 2001-11-15
WO2001085796A3 true WO2001085796A3 (en) 2002-04-04

Family

ID=8171493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/005478 WO2001085796A2 (en) 2000-05-12 2001-05-10 Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage

Country Status (10)

Country Link
US (8) US7482004B2 (en)
EP (1) EP1297016B1 (en)
AT (1) ATE321069T1 (en)
AU (2) AU6595301A (en)
CA (1) CA2407858C (en)
DE (1) DE60118186T2 (en)
DK (1) DK1297016T3 (en)
ES (1) ES2260234T3 (en)
PT (1) PT1297016E (en)
WO (1) WO2001085796A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085796A2 (en) * 2000-05-12 2001-11-15 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
KR20020059609A (en) * 2000-08-04 2002-07-13 벤슨 로버트 에이치. Vascular endothelial growth factor 2
GB2374870A (en) * 2001-01-26 2002-10-30 Thromb X Nv Use of genetically modified multicellular animals in the identification of drug target proteins
CA2444632A1 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
WO2002083849A2 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
GB2384706A (en) * 2002-02-04 2003-08-06 Thromb X Nv Agent for the prevention or minimisation of post-operative adhesion formation and/or cell implantation
ITRM20020277A1 (en) * 2002-05-17 2003-11-17 Geymonat Spa TYPE 1 PLACENTAR GROWTH FACTOR MUTEINE, PREPARATION METHOD AND THEIR APPLICATIONS.
ATE357255T1 (en) * 2002-06-28 2007-04-15 Vlaams Interuniv Inst Biotech PLACENTA GROWTH FACTOR AS A TARGET FOR THE TREATMENT OF OSTEOPOROSIS
AU2003288027A1 (en) * 2002-11-16 2004-06-15 Dade Behring Marburg Gmbh Scd40l, papp-a and placental growth factor (plgf) used as a biochemical marker combination in cardiovascular diseases
GB0228409D0 (en) * 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
EP1601696A1 (en) * 2003-03-07 2005-12-07 AnGes MG, Inc. Compositions and methods for inhibiting inflammation of vessel walls and formation of neointimal hyperplasia
MXPA06002296A (en) 2003-08-29 2006-05-22 Pfizer Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents.
MXPA06007242A (en) 2003-12-23 2006-08-18 Pfizer Novel quinoline derivatives.
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
EP1812064A4 (en) * 2004-11-19 2009-07-08 Cornell Res Foundation Inc Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
EA013970B1 (en) 2005-03-24 2010-08-30 Тромбоджиникс Н.В. Novel anti-plgf antibody and use thereof
DE102005022047A1 (en) 2005-05-09 2006-11-30 Dade Behring Marburg Gmbh Binding partner of the placental growth factor, in particular antibodies directed against the placental growth factor, their production and use
US7867490B2 (en) 2005-06-30 2011-01-11 Vib Vzw Treatment of liver cirrhosis and its complications
CN101534865A (en) * 2005-10-19 2009-09-16 Ibc药品公司 Methods and compositions for generating bioactive assemblies of increased complexity and uses
CN100355882C (en) * 2005-12-05 2007-12-19 中国人民解放军军事医学科学院放射与辐射医学研究所 Hybridoma cell strain and its produced human VEGFR-3 resistant monoclonal antibody
AU2014200453B2 (en) * 2006-11-09 2015-06-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differential gene expression in physiological and pathological angiogenesis
US20100028256A1 (en) * 2006-11-09 2010-02-04 St Croix Brad Differential gene expression in physiological and pathological angiogenesis
JP5797403B2 (en) 2007-08-03 2015-10-21 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント Human monoclonal antibody and method for producing the same
US8835183B2 (en) 2008-01-07 2014-09-16 Ortho-Clinical Diagnostics, Inc. Determination of sFlt-1:angiogenic factor complex
WO2009117791A2 (en) 2008-03-28 2009-10-01 Katholieke Universiteit Leuven Mucosal gene signatures
JP5766608B2 (en) 2008-10-02 2015-08-19 ヴェーイーベー ヴェーゼットウェーＶｉｂ Ｖｚｗ Inhibition of PlGF to treat Philadelphia chromosome positive leukemia
GB0914318D0 (en) 2009-08-14 2009-09-30 Medical Res Council Method
DE102010013555A1 (en) 2010-03-31 2011-10-06 Christian Hamm Use of biomarkers sFlt and PIGF in the diagnosis and treatment of pulmonary hypertension
WO2012151574A1 (en) 2011-05-05 2012-11-08 Duke University Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics
PL2785739T3 (en) 2011-12-01 2017-10-31 Thrombogenics Nv Improving trabeculectomy outcome
PT2838918T (en) 2012-04-20 2019-08-23 Merus Nv Methods and means for the production of heterodimeric ig-like molecules
AU2017231765A1 (en) * 2016-03-10 2018-08-23 Oxurion NV Posterior ocular fibrosis inhibition by antagonizing placental growth factor
US11499973B2 (en) 2016-05-17 2022-11-15 Duke University Methods of predicting responsiveness of a cancer to a VEGF targeting agent and methods of prognosing and treating cancer
KR20210062650A (en) * 2018-09-11 2021-05-31 앤비션 에스.알.엘. Peptide and its medical use
CN112996528A (en) * 2018-09-11 2021-06-18 安必圣有限责任公司 Peptides and medical uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919899A (en) * 1990-09-27 1999-07-06 Consiglio Nazionale Delle Ricerche Human protein with angiogenesis regulative properties

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US20010021382A1 (en) * 1991-03-29 2001-09-13 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1993020229A1 (en) * 1992-04-03 1993-10-14 Genentech, Inc. ANTIBODIES TO ALPHAvBETA3 INTEGRIN
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6846839B1 (en) * 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
US6986890B1 (en) * 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
US6455283B1 (en) * 1998-03-17 2002-09-24 Genentech, Inc. Nucleic acids encoding vascular endothelial cell growth factor-E (VEGF-E)
GB9723780D0 (en) * 1997-11-12 1998-01-07 Univ Manchester Regulation of ocular angiogenesis
WO1999060846A1 (en) 1998-05-26 1999-12-02 Innogenetics N.V. Method for expanding primate b cells selectively in immunocompromised mice and producing large numbers of antigen-specific b lymphocytes for the production of primate monoclonal antibodies
WO2001057067A1 (en) * 2000-02-04 2001-08-09 Supratek Pharma Inc. Ligand for vascular endothelial growth factor receptor
WO2001085796A2 (en) * 2000-05-12 2001-11-15 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
ATE357255T1 (en) * 2002-06-28 2007-04-15 Vlaams Interuniv Inst Biotech PLACENTA GROWTH FACTOR AS A TARGET FOR THE TREATMENT OF OSTEOPOROSIS
EA013970B1 (en) * 2005-03-24 2010-08-30 Тромбоджиникс Н.В. Novel anti-plgf antibody and use thereof
US7867490B2 (en) * 2005-06-30 2011-01-11 Vib Vzw Treatment of liver cirrhosis and its complications

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919899A (en) * 1990-09-27 1999-07-06 Consiglio Nazionale Delle Ricerche Human protein with angiogenesis regulative properties

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AHMED A ET AL: "Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen: A review.", PLACENTA, vol. 21, no. Suppl. A, March 2000 (2000-03-01), pages S16 - S24, XP001012707, ISSN: 0143-4004 *
BERNATCHEZ PASCAL N ET AL: "Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 43, 22 October 1999 (1999-10-22), pages 31047 - 31054, XP001018935, ISSN: 0021-9258 *
CARMELIET P: "Molecular mechanisms of normal and pathologic angiogenesis: Insights and therapeutic concepts from transgenic mice.", JOURNAL OF VASCULAR RESEARCH, vol. 37, no. Suppl. 1, May 2000 (2000-05-01), 21st European Conference on Microcirculation;Stockholm, Sweden; June 04-07, 2000, pages 79, XP001013620, ISSN: 1018-1172 *
DONNINI SANDRA ET AL: "Expression and localization of placenta growth factor and PlGF receptors in human meningiomas.", JOURNAL OF PATHOLOGY, vol. 189, no. 1, 1999, pages 66 - 71, XP001012781, ISSN: 0022-3417 *
KANNO S ET AL: "ROLES OF TWO VEGF RECEPTORS, FLT-1 AND KDR, IN THE SIGNAL TRANSDUCTION OF VEGF EFFECTS IN HUMAN VASCULAR ENDOTHELIAL CELLS", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 19, no. 17, 20 April 2000 (2000-04-20), pages 2138 - 2146, XP001012776, ISSN: 0950-9232 *
MIGDAL MICHAL ET AL: "Neuropilin-1 is a placenta growth factor-2 receptor.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 35, 28 August 1998 (1998-08-28), pages 22272 - 22278, XP000999223, ISSN: 0021-9258 *
PARRY T J ET AL: "Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 27, no. 13, 1 July 1999 (1999-07-01), pages 2569 - 2577, XP002168772, ISSN: 0305-1048 *
YONEKURA HIDETO ET AL: "Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 49, 3 December 1999 (1999-12-03), pages 35172 - 35178, XP001018934, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
DE60118186D1 (en) 2006-05-11
DE60118186T2 (en) 2006-12-28
US20120263710A1 (en) 2012-10-18
CA2407858C (en) 2015-10-27
CA2407858A1 (en) 2001-11-15
US20130177565A1 (en) 2013-07-11
DK1297016T3 (en) 2006-07-10
US20030180286A1 (en) 2003-09-25
ATE321069T1 (en) 2006-04-15
US7482004B2 (en) 2009-01-27
US20130183310A1 (en) 2013-07-18
EP1297016B1 (en) 2006-03-22
PT1297016E (en) 2006-07-31
AU6595301A (en) 2001-11-20
WO2001085796A2 (en) 2001-11-15
US20090162354A1 (en) 2009-06-25
AU2001265953B2 (en) 2005-09-29
ES2260234T3 (en) 2006-11-01
US20090074765A1 (en) 2009-03-19
US20090238826A1 (en) 2009-09-24
EP1297016A2 (en) 2003-04-02
US20130177564A1 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
WO2001085796A3 (en) Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
DK1107794T3 (en) Therapeutic preparations for the treatment of mucus hypersecretion
WO2010065072A8 (en) Antagonists of il-6 to raise albumin and/or lower crp
WO2011066369A3 (en) Antagonists of il-6 to raise albumin and/or lower crp
DE60315355D1 (en) Piperidinol-thiazole-carboxylic acid derivates as angiogenesis inhibitors
WO2007015866A3 (en) Inhibitors of p38 kinase and methods of treating inflammatory disorders
WO2004059318A3 (en) Methods of detecting the inhibition of fibrocyte formation and methods and compositions for enhancing fibrocyte formation
IL185754A0 (en) Novel anti-plgf antibody
WO2006086544A3 (en) Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
JP2019506159A5 (en)
NO20063300L (en) Methods for treating acute inflammation in animals with p38 MAP kinase inhibitors
WO2003020906A3 (en) Multivalent protein conjugate with multiple ligand-binding domains of receptors
MXPA03006806A (en) Method of using a variant of vegf receptor to treat psoriasis and to enhance wound healing.
WO2002092008A3 (en) Use of il-18 inhibitors for the treatement or prevention of sepsis
WO2007124414A3 (en) Cxcl13 antagonists and their use for the treatment of inflammatory diseases
WO2005112903A3 (en) Use of ghrelin antagonists for improving cognition and memory
NO20085135L (en) Selective inhibitors of ROCK protein kinase and its use
MA25847A1 (en) COMPOSITION FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION.
WO2004001065A3 (en) Exhaustive selection or rna aptamers against complex targets
WO2001094951A3 (en) Inhibitors of c-reactive protein induced inflammation
WO2002060869A3 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
WO2002076434A3 (en) Nicotinic receptor agonists for the treatment of inflammatory diseases
WO2004032709A3 (en) Inhibition of src for treatment of reperfusion injury related to revascularization
WO2004012656A3 (en) Thiophene and furan derivatives as prostaglandin agonists and use thereof
WO2004012660A3 (en) Mk2 interacting proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2407858

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001265953

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10291979

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001943357

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001943357

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001265953

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2001943357

Country of ref document: EP